Studi clinici su Obesità nello stato di Tennessee
38 studi su Obesità cercano partecipanti presso sedi nello stato di Tennessee.
Città nello stato di Tennessee
Testo ufficiale dello studio (inglese)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Holston Medical Group - Bristol /ID# 282045, Bristol
- New Phase Research & Development /ID# 282131, Knoxville
- Summit Medical Group- Halls Family Physicians /ID# 282435, Knoxville
- e altri 1
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 2 ott 2026 · NCT07752979AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
- M3 Wake Research Chattanooga, Chattanooga
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07533175A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- LifeDoc Health, Memphis
In reclutamentoFase 3
Età da 8 a 18 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07253285Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- AMR Clinical, Nashville
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 28 set 2026 · NCT07837973Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Gastroenterology Center Of The Midsouth, Cordova
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937099A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- Vanderbilt Health One Hundred Oaks, Nashville
In reclutamentoFase 3
Età da 6 a 17 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06672549Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
- Gastroenterology Center Of The Midsouth, Cordova
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937086A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
- Research Site, Franklin
- Research Site, Jackson
- Research Site, Knoxville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07784270Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Stern Cardiovascular Foundation Inc, Germantown
- Accellacare of Knoxville, Knoxville
- Cardiovascular Research of Knoxville North Knoxville Medical Center, Powell
- e altri 1
In reclutamentoFase 3
Età da 45 a 99 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07589608Transition to Ambulatory Bariatric Surgery (TABS) Trial
- Vanderbilt University Medical Center, Nashville
In reclutamento
Età da 25 a 55 · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07011628A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Memphis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Memphis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07743450Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
- Apex Research Foundation, LLC, Jackson
- The Jackson Clinic PA, Jackson
- Parkway Cardiology Associates, Oak Ridge
- e altri 2
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 16 set 2026 · NCT07037459A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Innovative Clinical Research, Clarksville
- Clinical Research Associates, Nashville
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 14 set 2026 · NCT07351045A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Nashville
In reclutamentoFase 3Volontari sani benvenuti
Età da 18 a 79 · Tutti i sessi · Aggiornato il 11 set 2026 · NCT07654374A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Quality Medical Research, Nashville
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 8 set 2026 · NCT06143956A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- DelRicht Research - Thompson's Station, Smyrna
In reclutamentoFase 4
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 set 2026 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailea Clinical Site, Memphis
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- New Phase Research and Development, Knoxville
In reclutamentoFase 3
Età da 18 a 99 · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chattanooga
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 3 set 2026 · NCT07284875The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 1/2
Età 18 e oltre · Tutti i sessi · Aggiornato il 1 set 2026 · NCT05972564A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Kingsport
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 ago 2026 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- Balad Hlth Sys-Welmont CardCVA, Greeneville
- The Jackson Clinic, PA, Jackson
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 18 ago 2026 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Knoxville
In reclutamentoFase 3
Età da 18 a 79 · Tutti i sessi · Aggiornato il 10 ago 2026 · NCT07654361Atomoxetine in Melanocortin Obesity Syndrome
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 2
Età 6 e oltre · Tutti i sessi · Aggiornato il 7 ago 2026 · NCT06899178A Study to Improve Skeletal Muscle in Veterans With HIV
- Tennessee Valley Healthcare System Nashville Campus, Nashville, TN, Nashville
In reclutamento
Età da 20 a 80 · Uomini · Aggiornato il 26 giu 2026 · NCT06845046Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
- Holston Medical Group_Bristol, Bristol
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 25 giu 2026 · NCT07607587Daily Eating Patterns for Total Health Study
- Healthy Eating and Activity Laboratory, Knoxville
In reclutamento
Età da 25 a 60 · Tutti i sessi · Aggiornato il 15 giu 2026 · NCT06455995A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity
- MBX Biosciences Investigational Site, Knoxville
In reclutamentoFase 1
Età da 18 a 65 · Tutti i sessi · Aggiornato il 9 giu 2026 · NCT07142707EBT Fruit and Vegetable Prescription
- Cherokee Health Systems, Dameron Avenue Pedatrics, Knoxville
In reclutamentoVolontari sani benvenuti
Età da 4 a 10 · Tutti i sessi · Aggiornato il 9 giu 2026 · NCT05028205Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity
- St. Jude Children's Research Hospital, Memphis
In reclutamentoFase 2
Età 18 e oltre · Tutti i sessi · Aggiornato il 4 giu 2026 · NCT07228741Metabolic Effects of Angiotensin-(1-7)
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 1
Età da 18 a 60 · Tutti i sessi · Aggiornato il 22 mag 2026 · NCT02646475Sympathetic Mechanisms in Obesity-Crossover Design
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 1/2
Età da 18 a 65 · Tutti i sessi · Aggiornato il 27 feb 2026 · NCT05312892A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment
- Vanderbilt University Medical Center (Part C only), Nashville
In reclutamentoFase 1/2Volontari sani benvenuti
Età da 12 a 65 · Tutti i sessi · Aggiornato il 22 dic 2025 · NCT06239116Tirzepatide in PWS, HO and GNSO
- Vanderbilt University Medical Center, Nashville
In reclutamentoFase 4
Età da 18 a 26 · Tutti i sessi · Aggiornato il 16 set 2025 · NCT06901245Relationship Between Aspirin Metabolism and Markers of Metabolic Dysfunction Among Pregnant Persons at Risk of Pre-eclampsia
- University of Tennessee Medical Center, Knoxville
In reclutamentoStudio osservazionale
Età da 18 a 45 · Donne · Aggiornato il 10 set 2025 · NCT06802861Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.